Rotator Cuff Tendon Repair With FiberLocker System Patch Augmentation

NCT ID: NCT07005063

Last Updated: 2025-07-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-07-03

Study Completion Date

2029-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The overall objective of this clinical investigation is to assess the safety and efficacy of full-thickness arthroscopic rotator cuff repairs augmented with the FiberLocker System for the subjects. The primary outcome of the investigation is to assess the safety after full-thickness arthroscopic rotator cuff repairs augmented with the FiberLocker System in terms of postoperative adverse events through the 12-month follow-up. Main secondary outcomes include measures of efficacy and clinical performance evaluated at 6-week, 4.5-month, and 12-month follow-ups including retear rate assessed using MRI and different functional performance scores.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rotator Cuff Tear Rotator Cuff Injury Rotator Cuff Rupture

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Augmentation of Rotator Cuff Repair using the FiberLocker System

All enrolled participants will undergo repair of the rotator cuff tear, with augmentation utilizing the FiberLocker System.

Group Type EXPERIMENTAL

FiberLocker® System (encompassing SpeedPatch® PET and FiberLocker Instrument® SN)

Intervention Type DEVICE

The FiberLocker® System is a mechanical augmentation system that includes an implant (SpeedPatch® PET) and an instrument (FiberLocker® Instrument SN) for its attachment. The implant is composed of non-woven PET fibers, and the instrument features a reciprocating needle at its tip, which pushes the individual patch fibers into the underlying tendon tissue

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

FiberLocker® System (encompassing SpeedPatch® PET and FiberLocker Instrument® SN)

The FiberLocker® System is a mechanical augmentation system that includes an implant (SpeedPatch® PET) and an instrument (FiberLocker® Instrument SN) for its attachment. The implant is composed of non-woven PET fibers, and the instrument features a reciprocating needle at its tip, which pushes the individual patch fibers into the underlying tendon tissue

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject requires surgical treatment of a full-thickness rotator cuff tear, according to Balgrist standard procedure
2. Full-thickness tear of the supraspinatus or combined infraspinatus and supraspinatus
3. The rotator cuff tear is of traumatic origin.
4. Subject is ≥ 40 years of age \& ≤ 65 years of age.
5. Primary rotator cuff repair
6. Informed Consent signed by the subject
7. Pre-operative MRI performed

Exclusion Criteria

1. Vulnerable subjects (as defined in ISO 14155)
2. Subjects who do not have the power of judgement or are unable to fully understand all aspects of the investigation that are relevant to the decision to participate
3. Participation in another investigation with an investigational drug or another MD within the 30 days preceding and during the present investigation,
4. Previous enrolment into the current investigation,
5. Enrolment of the PI, his/her family members, employees and other dependent persons,
6. Inability to follow the procedures of the investigation, or known or suspected non-compliance, e.g. due to language problems, psychological disorders, dementia, drug or alcohol abuse, etc. of the subject
7. Active smoker
8. History of claustrophobia that would prevent an MRI of the index shoulder
9. Presence of an implanted metallic device or other implants that would contraindicate acquisition or inhibit radiologist review of an MRI of the index shoulder
10. Pregnant or planning to become pregnant during the study period
11. Breast feeding women
12. Subject has conditions or circumstances that would interfere with study requirements.
13. Contraindications and limitations of the MD as described in the IFUs.
14. Partial rotator cuff tears
15. History or known allergy or intolerance to polyester
16. Complete full-thickness subscapularis tears greater than the superior 1/3 of the tendon, with Lafosse grade 3 or greater
17. Massive rotator cuff tears, tear size equal to or greater than 4 cm in the anterior-posterior dimension or irreparable rotator cuff tear
18. Limited space or exposure for implant delivery
19. Structural or pathological condition of the bone or soft tissue that could impair healing.
20. Intraoperative rotator cuff tear characteristics differ from preoperatively expected characteristics and fulfil one of the abovementioned criteria
21. Fatty infiltration of the index shoulder rotator cuff muscle \> Goutallier Score 2
22. Corticosteroid injection in the operative shoulder within 6 weeks of operation
23. Subject shows frozen shoulder/adhesive capsulitis at day of surgery
24. Cases of moderate to severe osteoarthritis
25. Patients with inflammatory disease or auto-immune based joint diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus, arthropathy)
26. Subjects with diabetes type I or II
27. The subject currently has an acute infection in the area surrounding the surgical site
28. Evidence of active infection, osteomyelitis, sepsis or distant infection which could spread to the index joint.
29. Any comorbidity or condition that renders the patient a poor surgical candidate as determined by the Investigator.
Minimum Eligible Age

40 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

ZuriMED Technologies AG

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Balgrist University Hospital

Zurich, Canton of Zurich, Switzerland

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Karl Wieser, Prof. Dr. med.

Role: primary

+41 44 386 30 12

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SNCTP000006378

Identifier Type: OTHER

Identifier Source: secondary_id

ZM072024

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Rotator Cuff Pathway
NCT03717753 COMPLETED NA